Two hundred eight pediatric neurologists completed the survey. Most respondents believed that pediatric neurologists should counsel WWE on: teratogenic antiseizure medications (99%, n=206/207), contraception-antiseizure medication interactions (96%, n=194/202), pregnancy (95%, n=198/206), contraception (89%, n=184/206), and folic acid supplementation (70%, n=144/205). However, significantly fewer respondents felt confident with such counseling (teratogenesis: 90%, n=188/208, drug interactions: 65%, n=133/208, pregnancy: 75%, n=156/208, contraception: 47-64%, n=96-134/208, p<0.05). Ninety-five percent (n=172/181) reported ever discussing SRH with typically developing adolescent and young adult WWE, compared with 78% (n=141/181) for WWE with mild intellectual disability (p<0.01). One third (n=56/170) of respondents who ever discussed SRH did not do so routinely. Respondents correctly answered 87% ± 5% of questions on general principles of SRH for WWE, 78% ± 4% of questions about teratogenic antiseizure medications, and 62% ± 7%  of questions about contraception-antiseizure drug interactions. The greatest barrier to SRH provision was time constraints (80%, n=149/186).  The majority (64%, n=119/186) identified potential solutions including longer appointment times, co-managing SRH with other specialties, and development of practice guidelines.